Recombinant adeno-associated virus (rAAV) has been developed as a successful vector for both basic research and human gene therapy. However. neutralizing antibodies (NAbs) against AAV capsids can abolish AAV infectivity on target cells. reducing the transduction efficacy. https://www.kvmrentals.com/product-category/previews-exclusive/